Search

Your search keyword '"Hogan, R. Edward"' showing total 271 results

Search Constraints

Start Over You searched for: Author "Hogan, R. Edward" Remove constraint Author: "Hogan, R. Edward"
271 results on '"Hogan, R. Edward"'

Search Results

1. Highlights From the Annual Meeting of the American Epilepsy Society 2022

8. Analyses of Patients Who Self-Administered Diazepam Nasal Spray for Acute Treatment of Seizure Clusters

12. Brain mapping in a patient with congenital blindness - a case for multimodal approaches.

13. Highlights From the Annual Meeting of the American Epilepsy Society 2022

18. Seizure-or Epilepsy-Related Emergency Department Visits Before and During the CoVID-19 Pandemic--United States, 2019-2021

19. Multimodal mapping of regional brain vulnerability to focal cortical dysplasia

20. Quiescence during burst suppression and postictal generalized EEG suppression are distinct patterns of activity

21. Safety of a Second Dose of Diazepam Nasal Spray Within 4 Hours in Patients With Seizure Clusters: Final Results From a Long-Term, Phase 3, Open-Label, Repeat-Dose Safety Study (P14-8.003)

22. Timing to Administration and Ease of Dosing of Diazepam Nasal Spray Rescue Therapy for Seizure Clusters: Results From a Phase 3, Long-Term Open-Label, Repeat-Dose Safety Study (P15-8.001)

24. Multicenter Validation of a Deep Learning Detection Algorithm for Focal Cortical Dysplasia

26. Correlating electroconvulsive therapy response to electroencephalographic markers: Study protocol.

27. Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study.

28. Highlights From AES2020, a Virtual American Epilepsy Society Experience

29. Safety Profile of Valtoco® (diazepam nasal spray) in Patients With Epilepsy: Final Results From a Phase 3, Open-Label, 12-Month Repeat Dose Safety Study (1753)

30. Time to Second Doses in Emergency Seizure Patients Treated With Valtoco® (diazepam nasal spray) Across 24 Hours: Subgroup Results From a Completed Phase 3, Open-label, Repeat Dose Safety Study (1756)

32. Evaluation of Diazepam Nasal Spray in Patients with Epilepsy Concomitantly Using Maintenance Benzodiazepines: Interim Analysis from a Phase 3, Long-term, Open-label Safety Study (1760)

33. The Role of SPECT and PET in Epilepsy

38. Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out‐of‐hospital seizure clusters: Results from a phase 3, open‐label, repeat‐dose safety study.

41. Safety and Tolerability of NRL-1, an Intranasal Formulation of Diazepam, in Relationship to Usage Frequency in Subjects With Epilepsy: Interim Results From a Phase 3, Open-label, Repeat Dose Study (1992)

42. Pharmacokinetics and Safety of Valtoco® (NRL-1; diazepam nasal spray) in Patients With Epilepsy During Seizure (Ictal/Peri-ictal) and Non-seizure (Inter-ictal) Conditions: Results from a Phase 1, Open-Label Study (1981)

43. Effectiveness and Safety of Valtoco® (NRL-1; diazepam nasal spray) in Patients With Epilepsy and a History of Seasonal Allergies: Interim Results From a Phase 3, Open-Label, 12-Month Repeat Dose Study (2048)

48. Central-Positive Complexes

Catalog

Books, media, physical & digital resources